PG

164.05

+0.9%↑

KO

71.35

+0.69%↑

PM

181.72

+0.09%↑

FMX

106.89

+1.52%↑

PEP

130

-0.76%↓

PG

164.05

+0.9%↑

KO

71.35

+0.69%↑

PM

181.72

+0.09%↑

FMX

106.89

+1.52%↑

PEP

130

-0.76%↓

PG

164.05

+0.9%↑

KO

71.35

+0.69%↑

PM

181.72

+0.09%↑

FMX

106.89

+1.52%↑

PEP

130

-0.76%↓

PG

164.05

+0.9%↑

KO

71.35

+0.69%↑

PM

181.72

+0.09%↑

FMX

106.89

+1.52%↑

PEP

130

-0.76%↓

PG

164.05

+0.9%↑

KO

71.35

+0.69%↑

PM

181.72

+0.09%↑

FMX

106.89

+1.52%↑

PEP

130

-0.76%↓

Search

Hims & Hers Health Inc

Open

SectorConsumer defensive

55.9 6.09

Overview

Share price change

24h

Current

Min

52.72

Max

57.41

Key metrics

By Trading Economics

Income

23M

49M

Sales

105M

586M

P/E

Sector Avg

83.485

41.373

EPS

0.2

Profit margin

8.444

Employees

1,637

EBITDA

48M

66M

Recommendations

By TipRanks

Recommendations

Neutral

12 Months Forecast

-21.49% downside

Dividends

By Dow Jones

Next Earnings

4 Aug 2025

Market Stats

By TradingEconomics

Market Cap

3.5B

13B

Previous open

49.81

Previous close

55.9

News Sentiment

By Acuity

50%

50%

69 / 151 Consumer defensive

Technical Score

By Trading Central

Confidence

Bullish Evidence

Hims & Hers Health Inc Chart

Past performance is not a reliable indicator of future results.

Related News

29 Apr 2025, 12:54 UTC

Major Market Movers

Hims & Hers Rallies After Novo Nordisk Deal on Wegovy

4 Apr 2025, 22:38 UTC

Hot Stocks

Stocks to Watch: Eli Lilly, Novo Nordisk, Hims & Hers, Maxeon Solar Technologies

1 Apr 2025, 23:15 UTC

Major Market Movers

Hims & Hers Adds Eli Lilly's Zepbound in Expansion of Weight-Loss Offerings -- 2nd Update

25 Feb 2025, 15:33 UTC

Major Market Movers

Novo Nordisk Shares Rise as Hims & Hers to Stop Mimicking Weight-Loss Drugs

18 Nov 2024, 19:07 UTC

Major Market Movers

Hims & Hers Stock Climbs After Former Regulator Autor Joins Board

14 Oct 2024, 15:02 UTC

Major Market Movers

Hims & Hers Health Shares Jump After FDA Set to Reconsider Limits on Knockoff Weight-Loss Drugs

3 Oct 2024, 11:28 UTC

Major Market Movers

Hims & Hers Health Shares Fall After FDA Removes Eli Lilly Obesity Drugs From Shortage List

3 Jun 2025, 15:03 UTC

Acquisitions, Mergers, Takeovers

Hims & Hers Seeks Growth in Europe as Weight-Loss Business Shifts -- Barrons.com

7 May 2025, 13:56 UTC

Earnings

Novo Nordisk Stock Jumps After Earnings. Compounding Market's Growth Took it By Surprise -- Barrons.com

6 May 2025, 14:24 UTC

Earnings

Hims & Hers Stock Is Higher After Earnings. The Sales Outlook Looks Low. -- Barrons.com

30 Apr 2025, 09:30 UTC

Top News

Why New Wegovy Deals Won't Restore Novo's Obesity Lead -- Heard on the Street -- WSJ

2 Apr 2025, 16:53 UTC

Top News

Hims & Hers Zepbound Offering Won't Bring Needed Sales Boom -- Analysis

19 Mar 2025, 15:54 UTC

Top News

Sale of Ozempic Knockoffs Are Supposed to End Soon. Telehealth Companies Aren't Happy. -- WSJ

21 Feb 2025, 23:20 UTC

Earnings

These Stocks Moved the Most Today: UnitedHealth, Alibaba, Rivian, Celsius, Booking, Block, Akamai, Hims & Hers, and More -- Barrons.com

10 Feb 2025, 12:00 UTC

Top News

Hims Super Bowl Ad Spotlights Weight-Loss Drug Copycats as Clock Ticks on Their Business -- Heard on the Street -- WSJ

19 Dec 2024, 17:16 UTC

Top News

FDA Says Shortage of Eli Lilly's Zepbound is Over, But Gives Compounders a Grace Period -- Barrons.com

19 Dec 2024, 15:14 UTC

Top News

Eli Lilly's Zepbound Shortage Is Officially Over, FDA Says -- Barrons.com

19 Dec 2024, 15:02 UTC

Top News

The Zepbound Shortage Is Officially Over, FDA Says -- Barrons.com

16 Dec 2024, 13:47 UTC

Top News

The Weight-Loss Drug Market Is Heading for a Reckoning This Week -- Barrons.com

16 Dec 2024, 07:00 UTC

Top News

The Weight-Loss Drug Market Is Heading for a Reckoning This Week. What to Expect. -- Barrons.com

3 Oct 2024, 14:45 UTC

Top News

Eli Lilly's Weight-Loss Drugs Are No Longer in Short Supply. Bad News for Hims & Hers. -- Barrons.com

3 Oct 2024, 13:12 UTC

Top News

Eli Lilly's Weight-Loss Drugs No Longer in Shortage. Bad News for Hims & Hers. -- Barrons.com

3 Oct 2024, 11:45 UTC

Top News

Update: Eli Lilly's Weight-Loss Drugs No Longer in Shortage. Bad News for Hims & Hers. -- Barrons.com

3 Oct 2024, 10:14 UTC

Top News

Update: Eli Lilly's Weight-Loss Drugs No Longer In Shortage. It's Bad News for These Stocks. -- Barrons.com

2 Aug 2024, 17:52 UTC

Acquisitions, Mergers, Takeovers

Hims & Hers Plan to Sell Knockoff Weight Loss Drug Looking Shaky -- Barrons.com

26 Jun 2024, 11:00 UTC

Top News
Acquisitions, Mergers, Takeovers

The War Over Cheaper Ozempic Won't End Well for Some Investors -- Heard on the Street -- WSJ

Peer Comparison

Price change

Hims & Hers Health Inc Forecast

Price Target

By TipRanks

-21.49% downside

12 Months Forecast

Average 42.09 USD  -21.49%

High 68 USD

Low 25 USD

Based on 11 Wall Street analysts offering 12 month price targets forHims & Hers Health Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

11 ratings

2

Buy

7

Hold

2

Sell

Technical Score

By Trading Central

36.685 / 52.35Support & Resistance

Short Term

Bullish Evidence

Intermediate Term

Bullish Evidence

Long Term

Bullish Evidence

Sentiment

By Acuity

69 / 151 Consumer defensive

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Hims & Hers Health Inc

Hims & Hers Health, Inc. operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides prescription medication on a recurring basis and ongoing care from healthcare providers; and over-the-counter drug and device products, cosmetics, and supplement products primarily focusing on general wellness, sexual health and wellness, skincare, and hair care. In addition, the company's curated non-prescription products include melatonin and biotin in the wellness specialty category; moisturizers, creams, sunscreen, serum, face oil, and face wash in the skincare specialty; condoms, climax delay spray and wipes, vibrators, and lubricants in the sexual health and wellness specialty; and shampoos, conditioners, scalp scrubs, and topical treatments, such as minoxidil in the hair care specialty category. Further, it offers medical consultation and post-consultation support services, as well as health and wellness products through wholesale partners. Hims & Hers Health, Inc. is based in San Francisco, California.